ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic unive… Read more
ViGenCell Inc. (308080) - Net Assets
Latest net assets as of September 2025: ₩49.35 Billion KRW
Based on the latest financial reports, ViGenCell Inc. (308080) has net assets worth ₩49.35 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩58.73 Billion) and total liabilities (₩9.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩49.35 Billion |
| % of Total Assets | 84.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.43 |
ViGenCell Inc. - Net Assets Trend (2019–2024)
This chart illustrates how ViGenCell Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ViGenCell Inc. (2019–2024)
The table below shows the annual net assets of ViGenCell Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩58.03 Billion | -18.83% |
| 2023-12-31 | ₩71.49 Billion | -20.25% |
| 2022-12-31 | ₩89.64 Billion | -14.53% |
| 2021-12-31 | ₩104.89 Billion | +407.84% |
| 2020-12-31 | ₩-34.07 Billion | -34.59% |
| 2019-12-31 | ₩-25.32 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ViGenCell Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7178556215000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩9.63 Billion | 16.60% |
| Other Components | ₩150.72 Billion | 259.74% |
| Total Equity | ₩58.03 Billion | 100.00% |
ViGenCell Inc. Competitors by Market Cap
The table below lists competitors of ViGenCell Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hazer Group Limited
PINK:HZRGF
|
$64.17 Million |
|
Creditwest Faktoring AS
IS:CRDFA
|
$64.19 Million |
|
O3 Mining Inc
OTCQX:OIIIF
|
$64.22 Million |
|
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
|
$64.23 Million |
|
Pyrum Innovations AG
OL:PYRUM
|
$64.13 Million |
|
Pulmonx Corp
NASDAQ:LUNG
|
$64.13 Million |
|
Naked Wines plc
PINK:MJWNY
|
$64.13 Million |
|
Shenwan Hongyuan (H.K.) Limited
F:WAY
|
$64.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ViGenCell Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 71,489,172,830 to 58,025,759,630, a change of -13,463,413,200 (-18.8%).
- Net loss of 14,055,502,830 reduced equity.
- Share repurchases of 215,600,000 reduced equity.
- New share issuances of 215,600,000 increased equity.
- Other factors increased equity by 592,089,630.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-14.06 Billion | -24.22% |
| Share Repurchases | ₩215.60 Million | -0.37% |
| Share Issuances | ₩215.60 Million | +0.37% |
| Other Changes | ₩592.09 Million | +1.02% |
| Total Change | ₩- | -18.83% |
Book Value vs Market Value Analysis
This analysis compares ViGenCell Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩-1341.98 | ₩5830.00 | x |
| 2020-12-31 | ₩-1806.11 | ₩5830.00 | x |
| 2021-12-31 | ₩5554.16 | ₩5830.00 | x |
| 2022-12-31 | ₩4716.53 | ₩5830.00 | x |
| 2023-12-31 | ₩3730.05 | ₩5830.00 | x |
| 2024-12-31 | ₩3012.18 | ₩5830.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ViGenCell Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5038.79%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-24.22%) is below the historical average (-13.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -149218.83% | 0.00x | 0.00x | ₩-19.90 Billion |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-7.05 Billion |
| 2021 | -10.60% | 0.00% | 0.00x | 1.12x | ₩-21.60 Billion |
| 2022 | -19.40% | 0.00% | 0.00x | 1.11x | ₩-26.36 Billion |
| 2023 | -25.00% | 0.00% | 0.00x | 1.13x | ₩-25.02 Billion |
| 2024 | -24.22% | -5038.79% | 0.00x | 1.16x | ₩-19.86 Billion |
Industry Comparison
This section compares ViGenCell Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ViGenCell Inc. (308080) | ₩49.35 Billion | 0.00% | 0.19x | $64.13 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |